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BACKRGROUND: Evaluation of the efficacy of oral cyclosporine A as a prophylactic
agent in preventing second-eye involvement in Leber's hereditary optic neuropathy
(LHON) in a prospective, open-label, non-randomized, multicenter pilot study. Only
LHON patients aged 18 years or more, with confirmed primary mitochondrial DNA
mutations and strictly unilateral optic neuropathy occurring within 6 months prior to
enrolment, were included in the study. All these patients, receiving treatment with
oral cyclosporine (Neoral®, Novartis) at 2.5 mg/kg/day, were examined at three-
month intervals for a year. The primary endpoint was the best corrected visual acuity
in the unaffected eye; the secondary endpoints were the best corrected visual acuity
in the first eye affected, the mean visual field defect on automated perimetry, the
thickness of the perifoveal retinal ganglion cell inner plexiform layer, and the
thickness of the peripapillary retinal nerve fiber layer in both eyes.
RESULTS: Among the 24 patients referred to our institution with genetically
confirmed LHON, between July 2011 and April 2014, only five patients, four males
and one female, fulfilled the inclusion criteria. Age at enrolment ranged from 19 to
42 years (mean: 27.2 years; median: 26 years), four patients harbored the
m.11778G > A pathogenic variant, and one the m.14484 T > C pathogenic variant.
The time-interval between the onset of symptoms and inclusion in the study ranged
from 7 to 17 weeks (mean: 11.8 weeks; median: 9 weeks). Despite treatment with
oral cyclosporine A, all patients eventually experienced bilateral eye involvement,
occurring within 11-65 weeks after the initiation of treatment. Over the study time
period, the average best corrected visual acuity worsened in the first eye affected; by
the end of the study, both eyes were equally affected.
CONCLUSIONS: Oral cyclosporine, at 2.5 mg/kg/day, did not prevent second-eye
involvement in patients with strictly unilateral Leber's hereditary optic neuropathy.
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